Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 91
Filter
1.
Pharmazie ; 79(3): 67-71, 2024 May 15.
Article in English | MEDLINE | ID: mdl-38872272

ABSTRACT

We examined the mechanism by which 24(R)-ethyllophenol (MAB28) isolated from the branches of Morus alba caused neurite outgrowth in rat pheochromocytoma cells (PC12). MAB28 significantly promoted neurite outgrowth to a similar degree as the positive control, nerve growth factor (NGF). After incubation with MAB28 in PC12 cells, phosphorylation of extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and cyclic AMP response element-binding protein was detected, but the time course of phosphorylation was different from that induced by NGF. The expression of chloride intracellular channel protein 3 (CLIC3) was significantly decreased by MAB28. 5-Nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB), an outward rectifying chloride channel inhibitor, significantly promoted neurite outgrowth in PC12 cells. These data suggested that MAB28 could induce neurite outgrowth by downregulating CLIC3 expression.


Subject(s)
Morus , Neurites , Animals , PC12 Cells , Rats , Morus/chemistry , Neurites/drug effects , Neuronal Outgrowth/drug effects , Nerve Growth Factor/pharmacology , Phosphorylation , p38 Mitogen-Activated Protein Kinases/metabolism , Nitrobenzoates/pharmacology , Cyclic AMP Response Element-Binding Protein/metabolism , Phenols/pharmacology , Blotting, Western , Extracellular Signal-Regulated MAP Kinases/metabolism , Chloride Channels
5.
Neuroscience ; 218: 295-304, 2012 Aug 30.
Article in English | MEDLINE | ID: mdl-22609937

ABSTRACT

Prostaglandin (PG) F(2α) is one of the major prostanoids biosynthesized by cyclooxygenases (COXs) from arachidonic acid. Although it has been reported that there is a selective surge in PGF(2α) production in the hippocampus during kainic acid (KA)-induced seizure activity, the precise intra-hippocampal distribution of PGF(2α) has not been elucidated due to the paucity of effective histological techniques for detecting PGs in tissues. We investigated the tissue distribution of PGF(2α) in the rat hippocampus 30 min after KA injection by developing fixation and immunohistological-staining methods. To detect PGF(2α) directly on histological sections, we used systemic perfusion fixation with water-soluble carbodiimide fixative, followed by immersion of the brains in Zamboni's fixative. We then performed immunofluorescence staining with anti-PGF(2α) antibody, with negative control experiments used to confirm the staining specificity. Definitive immunolabeling for PGF(2α) was evident most markedly in pyramidal cells of the hippocampal cornu Ammonis (CA) 3 sector and neurons of the hilus in KA-treated rats. Immunolabeling for PGF(2α) was also evident in granule cells of the dentate gyrus. Double immunfluorescence staining revealed that PGF(2α)-immunopositive neurons expressed cytosolic phospholipases A(2), COX-2, and FP receptor. These results suggest that the major source of PGF(2α) production immediately after KA injection was neurons of the hippocampal CA3 sector, hilus and dentate gyrus. These neurons exert PGF(2α)-mediated functions via FP receptors in an autocrine/paracrine manner and may play pathophysiological roles in the acute phase (30 min) of excitotoxicity.


Subject(s)
CA3 Region, Hippocampal/metabolism , Dinoprost/biosynthesis , Seizures/metabolism , Animals , CA3 Region, Hippocampal/drug effects , Convulsants/toxicity , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Immunohistochemistry , Kainic Acid/toxicity , Male , Rats , Rats, Wistar , Receptors, Prostaglandin/biosynthesis , Seizures/chemically induced , Staining and Labeling/methods
6.
Neuropathol Appl Neurobiol ; 38(6): 559-71, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22013984

ABSTRACT

AIMS: Multiple system atrophy (MSA) is pathologically characterized by the formation of α-synuclein-containing glial cytoplasmic inclusions (GCIs) in oligodendrocytes. However, the mechanisms of GCI formation are not fully understood. Cellular machinery for the formation of aggresomes has been linked to the biogenesis of the Lewy body, a characteristic α-synuclein-containing inclusion of Parkinson's disease and dementia with Lewy bodies. Here, we examined whether GCIs contain the components of aggresomes by immunohistochemistry. METHODS: Sections from five patients with MSA were stained immunohistochemically with antibodies against aggresome-related proteins and analysed in comparison with sections from five patients with no neurological disease. We evaluated the presence or absence of aggresome-related proteins in GCIs by double immunofluorescence and immunoelectron microscopy. RESULTS: GCIs were clearly immunolabelled with antibodies against aggresome-related proteins, such as γ-tubulin, histone deacetylase 6 (HDAC6) and 20S proteasome subunits. Neuronal cytoplasmic inclusions (NCIs) were also immunopositive for these aggresome-related proteins. Double immunofluorescence staining and quantitative analysis demonstrated that the majority of GCIs contained these proteins, as well as other aggresome-related proteins, such as Hsp70, Hsp90 and 62-kDa protein/sequestosome 1 (p62/SQSTM1). Immunoelectron microscopy demonstrated immunoreactivities for γ-tubulin and HDAC6 along the fibrils comprising GCIs. CONCLUSIONS: Our results indicate that GCIs, and probably NCIs, share at least some characteristics with aggresomes in terms of their protein components. Therefore, GCIs and NCIs may be another manifestation of aggresome-related inclusion bodies observed in neurodegenerative diseases.


Subject(s)
Brain/metabolism , Inclusion Bodies/metabolism , Multiple System Atrophy/metabolism , Neuroglia/metabolism , Aged , Aged, 80 and over , Brain/pathology , Female , Histone Deacetylase 6 , Histone Deacetylases/metabolism , Humans , Inclusion Bodies/pathology , Lewy Bodies/metabolism , Lewy Bodies/pathology , Male , Middle Aged , Multiple System Atrophy/pathology , Neuroglia/pathology , Neurons/metabolism , Neurons/pathology , Proteasome Endopeptidase Complex/metabolism , Tubulin/metabolism
8.
Ann Rheum Dis ; 68(2): 264-72, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18388159

ABSTRACT

OBJECTIVES: Systemic juvenile idiopathic arthritis (sJIA) is a rheumatic disease in childhood characterised by systemic symptoms and a relatively poor prognosis. Peripheral leukocytes are thought to play a pathological role in sJIA although the exact cause of the disease is still obscure. In this study, we aimed to clarify cellular functional abnormalities in sJIA. METHODS: We analysed the gene expression profile in peripheral leukocytes from 51 patients with sJIA, 6 patients with polyarticular type JIA (polyJIA) and 8 healthy children utilising DNA microarrays. Gene ontology analysis and network analysis were performed on the genes differentially expressed in sJIA to clarify the cellular functional abnormalities. RESULT: A total of 3491 genes were differentially expressed in patients with sJIA compared to healthy individuals. They were functionally categorised mainly into a defence response group and a metabolism group according to gene ontology, suggesting the possible abnormalities in these functions. In the defence response group, molecules predominantly constituting interferon (IFN)gamma and tumour necrosis factor (TNF) network cascades were upregulated. In the metabolism group, oxidative phosphorylation-related genes were downregulated, suggesting a mitochondrial disorder. Expression of mitochondrial DNA-encoded genes including cytochrome c oxidase subunit 1(MT-CO1) and MT-CO2 were suppressed in patients with sJIA but not in patients with polyJIA or healthy children. However, nuclear DNA-encoded cytochrome c oxidases were intact. CONCLUSION: Our findings suggest that sJIA is not only an immunological disease but also a metabolic disease involving mitochondria disorder.


Subject(s)
Arthritis, Juvenile/genetics , Cytokines/genetics , Mitochondria/genetics , Adolescent , Arthritis, Juvenile/immunology , Child , Child, Preschool , Computational Biology/methods , Cytokines/physiology , DNA, Mitochondrial/genetics , Female , Gene Expression Profiling/methods , Gene Expression Regulation , Gene Regulatory Networks , Humans , Male , Mitochondria/physiology , Oligonucleotide Array Sequence Analysis/methods , Severity of Illness Index , Young Adult
9.
Eur Respir J ; 31(2): 287-97, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17989120

ABSTRACT

Interleukin (IL)-18 production and pulmonary function were evaluated in patients with chronic obstructive pulmonary disease (COPD) in order to determine the role of IL-18 in COPD. Immunohistochemical techniques were used to examine IL-18 production in the lungs of patients with very severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV, n = 16), smokers (n = 27) and nonsmokers (n = 23). Serum cytokine levels and pulmonary function were analysed in patients with GOLD stage I-IV COPD (n = 62), smokers (n = 34) and nonsmokers (n = 47). Persistent and severe small airway inflammation was observed in the lungs of ex-smokers with very severe COPD. IL-18 proteins were strongly expressed in alveolar macrophages, CD8+ T-cells, and both the bronchiolar and alveolar epithelia in the lungs of COPD patients. Serum levels of IL-18 in COPD patients and smokers were significantly higher than those in nonsmokers. Moreover, serum levels of IL-18 in patients with GOLD stage III and IV COPD were significantly higher than in smokers and nonsmokers. There was a significant negative correlation between serum IL-18 level and the predicted forced expiratory volume in one second in patients with COPD. In contrast, serum levels of IL-4, IL-13 and interferon-gamma were not significantly increased in any of the three groups. In conclusion, overproduction of interleukin-18 in the lungs may be involved in the pathogenesis of chronic obstructive pulmonary disease.


Subject(s)
Forced Expiratory Volume , Interleukin-18/metabolism , Pulmonary Disease, Chronic Obstructive/mortality , Pulmonary Disease, Chronic Obstructive/pathology , Aged , Biomarkers/analysis , Cohort Studies , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunohistochemistry , Interferon-gamma/metabolism , Interleukin-13/metabolism , Male , Middle Aged , Predictive Value of Tests , Probability , Prognosis , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Function Tests , Risk Assessment , Sensitivity and Specificity , Severity of Illness Index , Survival Analysis
10.
Ann Rheum Dis ; 64(7): 1101-6, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15760930

ABSTRACT

OBJECTIVE: To prepare a website for families and health professionals containing up to date information about paediatric rheumatic diseases (PRD). METHODS: Firstly, paediatric rheumatology centres and family self help associations were surveyed to characterise current clinical practice of physicians providing care for children with PRD, research activities, and training facilities of each centre. Secondly, international consensus was reached on the content of the website. Finally, the website was developed and the texts translated. RESULTS: The web page contains three main sections: (a) description for families of the characteristics of 15 PRD; (b) list of paediatric rheumatology centres; (c) contact information for family self help associations. A version for 45 countries in 52 languages (with another three in progress) is now available on the web. 291 surveys from 171 centres and 102 family associations were received from 42 countries. The median proportion of time spent in paediatric practice in the centres examined was 100%, with 70% of this time dedicated to paediatric rheumatology. 90% of the centres were willing to perform clinical trials in the future. CONCLUSIONS: The PRINTO/PRES website provides a well defined and competent set of information about PRD, with appropriate multiple translated versions and easy web navigational direction.


Subject(s)
Internet , Pediatrics/education , Rheumatic Diseases/psychology , Rheumatology/education , Child , Education, Medical, Continuing/methods , Humans , Information Dissemination , International Cooperation , Patient Education as Topic
12.
Ryumachi ; 41(5): 864-8, 2001 Oct.
Article in Japanese | MEDLINE | ID: mdl-11729665

ABSTRACT

In Sjögren syndrome, purpura is one of its various well known eruptions. Although this disease state is assumed to be based on hypergammaglobulinemia, the details of its mechanism are unknown. We experienced a case involving a female patient with primary Sjögren syndrome showing repeated purpura on the legs, and examined her blood viscosity and histopathology. This girl developed Sjögren syndrome and was admitted to our hospital at 12-years-old. She underwent steroid treatment because of aggravation of the xerosis state and prominent purpura on the legs. Hypergammaglobulinemia was improved during the course; however, purpura appeared repeatedly. Although her blood viscosity was slightly higher than normal, this had no relation to purpura and serum gamma globulin values. Skin biopsy revealed necrotizing angiitis. These results suggest that the purpura of this case was caused not only by hyperviscosity from the hypergammaglobulinemia but also involvement of vasculitis by the primary disease.


Subject(s)
Purpura/etiology , Sjogren's Syndrome/complications , Adolescent , Female , Humans , Purpura/pathology , Recurrence
13.
Org Lett ; 3(18): 2915-8, 2001 Sep 06.
Article in English | MEDLINE | ID: mdl-11529789

ABSTRACT

[structure: see text]. Michael addition of various enolates toward gamma-CH(3-n)F(n)-alpha,beta-unsaturated ketones (n = 1-3) was proven to smoothly furnish the 1,4-adducts with high si face selectivities which monotonously decreased by reduction in the number of fluorines. Although the Felkin-Anh model correctly anticipates the present stereochemical outcome only with E-acceptors, the hyperconjugative stabilization of transition states by electron donation from the allylic substituents (the Cieplak rule) successfully explains the pi-facial preference of both acceptors at least in a qualitative level.

14.
J Rheumatol ; 28(7): 1677-80, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11469478

ABSTRACT

OBJECTIVE: To evaluate safety and efficacy of high dose etanercept (> 0.8 mg/kg, maximum 25 mg subcutaneously twice weekly) (Enbrel) in children with juvenile rheumatoid arthritis (JRA) and inadequate prior response to standard dose etanercept. METHODS: Retrospective chart review of 8 children (6 girls, 2 boys, mean age 8.4 yrs, range 5-16 yrs). Five children had systemic onset, polyarticular course JRA; 2 had polyarticular onset; and one had pauciarticular onset, polyarticular course JRA. All children had failed at least 3 mo (mean 9 mo) treatment with standard dose etanercept (0.4 mg/kg SC twice a week). All 8 children had increase in the etanercept dose to at least 0.8 mg/kg (mean 1.1 mg/kg, maximum 25 mg SC twice weekly) for a mean of 7 mo (range 3-10 mo). Efficacy of high dose etanercept was evaluated by changes in joint count, laboratory data, and ability to decrease concomitant medication. RESULTS: Improvements in the joint count and laboratory findings (erythrocyte sedimentation rate, hemoglobin and platelet count) were observed in 2 of 8 (25%) children. In these 2, concomitant prednisone was reduced or discontinued. In contrast, no changes in disease activity or laboratory findings were observed in the other 6 children. Overall, high dose etanercept was well tolerated. No laboratory abnormalities were detected and no child withdrew because of adverse events. CONCLUSION: High dose etanercept is safe and well tolerated in children, but efficacy seems limited. In children with unsatisfactory response to standard dose etanercept, an increased dose or treatment prolongation may not offer any additional benefit.


Subject(s)
Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Arthritis, Juvenile/drug therapy , Immunoglobulin G/administration & dosage , Immunoglobulin G/adverse effects , Receptors, Tumor Necrosis Factor/administration & dosage , Adolescent , Child , Child, Preschool , Etanercept , Female , Humans , Male , Retrospective Studies , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
15.
Arthritis Rheum ; 44(6): 1411-5, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11407702

ABSTRACT

OBJECTIVE: To evaluate the safety and efficacy of the tumor necrosis factor fusion protein etanercept in children with treatment-resistant uveitis. METHODS: Ten children with chronic active uveitis (7 girls and 3 boys, mean age 7.5 years [range 3-12 years]) were enrolled in this prospective study. In 7 children, uveitis was associated with pauciarticular juvenile rheumatoid arthritis. Five children were antinuclear antibody positive. All patients had failed previous therapy with topical steroids and methotrexate and/or cyclosporine. All were treated with etanercept at a dosage of 0.4 mg/kg twice weekly for the first 3 months, and then, if eyes did not improve, with 25 mg twice weekly (mean 1.1 mg/kg) for at least 3 additional months. RESULTS: At the beginning of the trial, uveitis affected 18 eyes in the 10 children. Within 3 months, 10 of 16 affected eyes (63%; P = 0.017) showed a rapid decrease in anterior chamber cell density, including remission of uveitis in 4 eyes. In children with visual acuity of less than 20/25, 4 of 10 eyes (40%) improved. An exacerbation of uveitis during etanercept therapy occurred in only 1 child (1 of 14 eyes [7%]). Other ocular outcome parameters, such as intraocular pressure, synechia formation, and lens clarity, remained unchanged. Following a dosage increase to an average of 1.1 mg/kg after 3 months in 7 children, no further improvement was noted. CONCLUSION: Our data suggest that etanercept injected subcutaneously twice a week has a beneficial effect on treatment-resistant chronic uveitis in children. Further controlled studies with etanercept in systemic or topical form are necessary to confirm its efficacy and optimal mode of administration.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/drug therapy , Immunoglobulin G/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Uveitis, Anterior/drug therapy , Administration, Topical , Antirheumatic Agents/administration & dosage , Arthritis, Juvenile/complications , Child , Child, Preschool , Cyclosporine/therapeutic use , Etanercept , Female , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Humans , Immunoglobulin G/administration & dosage , Injections, Subcutaneous , Male , Methotrexate/therapeutic use , Receptors, Tumor Necrosis Factor/administration & dosage , Recombinant Proteins , Treatment Outcome , Uveitis, Anterior/etiology , Vision Disorders/drug therapy , Vision Disorders/etiology , Visual Acuity
16.
J Rheumatol ; 28(4): 860-4, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11327263

ABSTRACT

OBJECTIVE: To investigate the prevalence of anti-alpha-fodrin antibody specific for adult Sjögren's syndrome (SS) in patients with juvenile onset SS. METHODS: Serum anti-alpha-fodrin antibody was examined in 15 patients with juvenile SS (11 cases of primary SS and 4 secondary SS) and in 16 children with systemic lupus erythematosus (SLE) by Western blot analysis using a recombinant 120 kDa alpha-fodrin fusion protein. RESULTS: All the 15 serum samples from patients with SS reacted with a recombinant alpha-fodrin fusion protein in Western blot analysis. In contrast, reactivity was found in only 2 of the 16 patients with SLE. The clinical features of the 15 patients with juvenile onset SS were very specific; only 4 patients complained of dryness, while 6 had abnormal excretion ability. Salivary gland enlargement was the most common clinical manifestation. Characteristic laboratory findings in juvenile onset SS included a higher prevalence of antinuclear antibodies, anti-SSA/Ro antibodies, and rheumatoid factor, as well as increased erythrocyte sedimentation rate and hypergammaglobulinemia. CONCLUSION: The pathogenesis of juvenile SS seems to be the same as that of adult SS, although subjective symptoms of dryness are less frequent in juvenile cases. This discrepancy may indicate that SS is a slowly progressive disease with a long time span. The anti-alpha-fodrin antibody is likely to be a reliable diagnostic marker for juvenile SS.


Subject(s)
Autoantibodies/analysis , Carrier Proteins/immunology , Microfilament Proteins/immunology , Sjogren's Syndrome/immunology , Adolescent , Blotting, Western , Child , Child, Preschool , Female , Humans , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/physiopathology , Male , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/pathology , Sjogren's Syndrome/physiopathology
17.
J Microsc ; 202(Pt 2): 391-4, 2001 May.
Article in English | MEDLINE | ID: mdl-11309101

ABSTRACT

Results of reflection microscopy and local reflection spectroscopy of J-aggregates of two pseudoisocyanine dyes in a thin film polymer matrix are reported. The individual J-aggregates assemble into fibre-like shapes of large structural heterogeneity. Reflectance spectra obtained at different samples, different locations on one sample and even at different positions of the same aggregate fibre reveal a wide distribution of optical properties. The shapes and absolute reflectivities of the spectra are suggested to originate from varying strengths of exciton-photon interaction and from the effect of finite thickness of the aggregate fibres. Polarization dependence measurements of local reflectivities provide orientations of the exciton transition dipole moments at 572 nm and 540 nm with respect to the orientation of the aggregate fibres. Furthermore, modified synthesis of capped semiconductor nanocrystals of CdSe is presented. The method yields high quality quantum dots suitable for microscopic imaging and spectroscopy.

18.
Clin Exp Rheumatol ; 19(6): 639-46, 2001.
Article in English | MEDLINE | ID: mdl-11791634

ABSTRACT

OBJECTIVE: To evaluate the safety and efficacy of L-asparaginase as an immunosuppressive agent in a mouse model of rheumatoid arthritis. METHODS: Male DBA/1 mice with collagen-induced arthritis (CIA) were treated at different intervals with various doses of native and pegylated L-asparaginase from E. coli. The mice were observed for 4 weeks during which time arthritis was scored. Outcome parameters included effect on severity and progression of established arthritis as well as prevention of disease. In addition, X-rays from the affected joints were obtained for comparison. RESULTS: Both native L-asparaginase at a dose of 50 IU/injection intraperitoneally three days a week and pegylated asparaginase (PEG-L-asparaginase) at a dose of 25 IU/injection twice a week, significantly reduced the mean arthritic score (MAS) in mice with established arthritis (p < 0.001 for PEG-L-asparaginase). When native L-asparaginase was administered before the onset of arthritis (days 14-post immunization) the number of mice developing arthritis as well as the number of arthritic paws and the severity of arthritis in the treatment group were significantly decreased (p < 0.0001). Significant differences were found in the X-ray evaluation between treated and control mice. None of the animals died due to drug related events or showed signs of asparaginase induced toxicity. CONCLUSION: Our data provide the first direct evidence that L-asparaginase is a potent antiarthritic agent and may represent an effective second line agent for future treatment studies in juvenile and adult rheumatoid arthritis.


Subject(s)
Antineoplastic Agents/therapeutic use , Arthritis, Experimental/drug therapy , Asparaginase/therapeutic use , Animals , Arthritis, Experimental/physiopathology , Arthrography , Dose-Response Relationship, Drug , Drug Combinations , Escherichia coli/immunology , Joints/drug effects , Joints/physiopathology , Lipopolysaccharides/pharmacology , Male , Mice , Mice, Inbred DBA , Polyethylene Glycols/therapeutic use , Treatment Outcome
19.
Nihon Ronen Igakkai Zasshi ; 37(8): 613-8, 2000 Aug.
Article in Japanese | MEDLINE | ID: mdl-11086386

ABSTRACT

From September 1995 through May 1999, percutaneous endoscopic gastrostomy (PEG) was performed in 47 elderly patients, aged 65 to 93 (average 78.9). Several treatments were additionally performed to prevent serious complications in these cases, and their usefulness and problems were investigated. Gastropexy was performed to prevent peritonitis in cases of self-removal of tubes in the acute stage. Intraoperative fluoroscopy was used prevent perforation of the intestines. However, re-insertion of the endoscopic, which was necessary with the push method, was omitted to reduce the burden on the patients. In patients with tube troubles in the chronic stage such as the buried bumper syndrome or self-removal, the existing fistula was preserved and the gastrostomy was reconstructed using a narrow polyvinyl chloride tube and a flexible guide wire to prevent peritonitis by erroneous insertion of the tube. In terms of results, gastropexy was useful to prevent peritonitis in one patient with early self-removal of the tube. Data to evaluate the usefulness of fluoroscopy in preventing perforation of the intestine were insufficient, so more patients need to be studied in the future. Even when confirmation of the location of the internal bumper by endoscopy was omitted, there was no case of poor traction of the bumper, so this procedure seems unnecessary. Review of tube troubles, in the chronic stage revealed no case of peritonitis caused by erroneous insertion of tubes or erroneous injection of nutrients with our reconstruction methods, and complete reconstruction of the gastrostomy with preservation of the existing fistula appeared to be possible. However, those additional treatments require extension of the operation time and rise in cost with increased use of medical instruments, so the indications should be carefully considered.


Subject(s)
Cerebrovascular Disorders/surgery , Deglutition Disorders/surgery , Endoscopy, Gastrointestinal/methods , Gastrostomy/methods , Postoperative Complications/prevention & control , Aged , Aged, 80 and over , Female , Humans , Male
20.
J Am Acad Dermatol ; 43(5 Pt 2): 969-71, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11044836

ABSTRACT

Symptoms of early onset sarcoidosis characterized by skin eruptions, arthritis, and uveitis mimic those of systemic type juvenile rheumatoid arthritis (JRA). We report 2 Japanese patients with early onset sarcoidosis, both of whom were initially diagnosed and treated as having JRA. Intermittent fever and synovial swelling may mask sarcoidosis in children less than 4 years old.


Subject(s)
Arthritis, Juvenile/diagnosis , Sarcoidosis/diagnosis , Skin Diseases/diagnosis , Child , Diagnosis, Differential , Humans , Male , Sarcoidosis/pathology , Skin/pathology , Skin Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...